In the current study, we investigated the in-vitro effect of a TLR7/8 agonist, Resiquimod, on the gene expression of mTOR and HIF-1α as an indicator of metabolic reprogramming in malignant CLL B cells as compared to normal B cells. Here, HIF1A is linked to B-cell chronic lymphocytic leukemia.